EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Combination of novel oncolytic herpesvirus with paclitaxel as an efficient strategy for breast cancer therapy

Xinyue Deng iD, Yinan Shen, Ming Yi, Chaomei Zhang, Bin Zhao, Guansheng Zhong, WeiyangLou, Dixuan Xue, Qi Leng, Jun Ding, Ronghua Zhao, Weiguo Jia und 2 weitere

Journal of Medical Virology · 2023

DOI: 10.1002/jmv.28768 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2023. Verfasst von Xinyue Deng und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. Hauptthemen laut MEDLINE: Oncolytic Virotherapy, Oncolytic Viruses, Neoplasms, Herpesvirus 1, Human. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

New strategies are needed to improve the treatment of patients with breast cancer (BC). Oncolytic virotherapy is a promising new tool for cancer treatment but still has a limited overall durable antitumor response. A novel replicable recombinant oncolytic herpes simplex virus type 1 called VG161 has been developed and has demonstrated antitumor effects in several cancers. Here, we explored the efficacy and the antitumor immune response of VG161 cotreatment with paclitaxel (PTX) which as a novel oncolytic viral immunotherapy for BC.

Methods

The antitumor effect of VG161 and PTX was confirmed in a BC xenograft mouse model. The immunostimulatory pathways were tested by RNA‐seq and the remodeling of tumor microenvironment was detected by Flow cytometry analysis or Immunohistochemistry. Pulmonary lesions were analyzed by the EMT6‐Luc BC model.

Results

In this report, we demonstrate that VG161 can significantly represses BC growth and elicit a robust antitumor immune response in a mouse model. The effect is amplified when combined with PTX treatment. The antitumor effect is associated with the infiltration of lymphoid cells, including CD4 + T cells, CD8 + T cells, and NK cells (expressing TNF and IFN‐γ), and myeloid cells, including macrophages, myeloid‐derived suppressor cells, and dendritic cell cells. Additionally, VG161 cotreatment with PTX showed a significant reduction in BC lung metastasis, which may result from the enhanced CD4 + and CD8 + T cell‐mediated responses.

Conclusions

The combination of PTX and VG161 is effective for repressing BC growth by inducing proinflammatory changes in the tumor microenvironment and reducing BC pulmonary metastasis. These data will provide a new strategy and valuable insight for oncolytic virus therapy applications in primary solid or metastatic BC tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oncolytic VirotherapyOncolytic VirusesNeoplasmsHerpesvirus 1, HumanHumansAnimalsMicePaclitaxelCD8-Positive T-LymphocytesCell Line, TumorTumor Microenvironment

Stichwörter der Autor:innen

PTXVG161breast cancerlung metastasistumor microenvironment

Substanzen

Paclitaxel

Autor:innen und Institutionen

  • Department of Breast Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
  • Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
  • Zhejiang Provincial Key Laboratory of Pancreatic Disease, Hangzhou, China.
  • Department of Geriatics, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Shanghai Virogin Biotech Co. Ltd., Shanghai, China.
  • CNBG-Virogin Biotech (Shanghai) Co. Ltd., Shanghai, China.

ORCID-Profile: Xinyue Deng

Zitieren

APA

Deng, X., Shen, Y., Yi, M., Zhang, C., Zhao, B., Zhong, G., WeiyangLou, Xue, D., Leng, Q., Ding, J., Zhao, R., Jia, W., Dong, C., & Dai, Z. (2023). Combination of novel oncolytic herpesvirus with paclitaxel as an efficient strategy for breast cancer therapy. Journal of Medical Virology. https://doi.org/10.1002/jmv.28768

Vancouver

Deng X, Shen Y, Yi M, Zhang C, Zhao B, Zhong G, et al. Combination of novel oncolytic herpesvirus with paclitaxel as an efficient strategy for breast cancer therapy. Journal of Medical Virology. 2023. doi:10.1002/jmv.28768

BibTeX
@article{Deng2023,
  author = {Deng, Xinyue and Shen, Yinan and Yi, Ming and Zhang, Chaomei and Zhao, Bin and Zhong, Guansheng and WeiyangLou and Xue, Dixuan and Leng, Qi and Ding, Jun and Zhao, Ronghua and Jia, Weiguo and Dong, Chenfang and Dai, Zhijun},
  title = {Combination of novel oncolytic herpesvirus with paclitaxel as an efficient strategy for breast cancer therapy},
  journal = {Journal of Medical Virology},
  year = {2023},
  doi = {10.1002/jmv.28768}
}
Kostenlos starten →